⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Incyte presenterà gli ultimi dati sull'idrosadenite suppurativa (HS) al Meeting annuale 2026 della American Academy of Dermatology (AAD)
businesswire.com
INCY
Incyte presentará los últimos datos sobre la hidradenitis supurativa en el Congreso Anual de la Academia Estadounidense de Dermatología (AAD) de este año
businesswire.com
INCY
Incyte wird auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) die neuesten Daten aus der Hidradenitis suppurativa-Forschung vorstellen
businesswire.com
INCY
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
businesswire.com
INCY
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
globenewswire.com
INCY
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
globenewswire.com
INCY
CMS(867.HK/8A8.SG):Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
globenewswire.com
INCY
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
prnewswire.com
GILD
INCY
BIIB
NVS
AMGN
JNJ
ABBV
BMY
AZN
MRK
PFE
TGTX
XNCR
CABA
IMUX
ZNTL
GLPG
CLNN
AUTL
Incyte annonce l’autorisation par la Commission européenne de Zynyz ® (rétifanlimab) pour le traitement de première intention du carcinome épidermoïde avancé du canal anal (SCAC)
businesswire.com
INCY
Incyte annuncia l'approvazione da parte della Commissione europea di Zynyz ® (retifanlimab) come terapia di prima linea del carcinoma anale a cellule squamose (SCAC) in fase avanzata
businesswire.com
INCY